Research output per year
Research output per year
Personal profile
Biography
| lid raad van bestuur | Prinses Maxima Centrum voor Kinderoncologie | 1-10-2019 |
| adviseur | CCCMünchen | 1-1-2022 |
| adviseur | Deutsche Krebshilfe | 1-9-2019 |
| adviseur | DKFZ-Heidelberg | 1-1-2020 |
| Editor-in-chief | Eur J Cancer | 1-1-2020 |
| chairman board | Fondation Cancer, B | 1-1-2015 |
| member | DSMB Melanoma Trials NKI-AvL | 1-1-2018 |
| board member | SAB Ludwig Cancer Inst Lausanne | 1-1-2022 |
| board member | EORTC Foundation Board | 1-1-2011 |
| IDMCimmuno member | IKR/AvL | 1-1-2021 |
| Advisory board | Agenus | 1-1-2021 |
| Advisory board/DSMB | Biocad | 1-1-2020 |
| Advisory board | BioInvent | 1-1-2020 |
| IDMC | BioNTech | 1-1-2020 |
| Advisory board | CatalYm | 1-1-2022 |
| Advisory board | Clover | 1-1-2017 |
| Advisory board | Ellipses | 1-9-2021 |
| Advisory board | Galecto | 1-1-2019 |
| Advisory board/IDMC | GSK | 1-1-2020 |
| Advisory board | IO Biotech | 1-2-2022 |
| Advisory board | Merck | 1-1-2019 |
| IDMC | Pfizer | 1-6-2019 |
| Advisory board | Sairopa | 1-6-2021 |
| Advisory board | Sellas | 1-1-2018 |
| Advisory board | SkylineDx | 1-1-2020 |
| Advisory board | TigaTx | 1-7-2021 |
| Advisory board | TTxDiscovery | 1-10-2021 |
| Lezingen Melanoma | Biocad, BMS, MSD | 1-1-2021 |
External positions
Lid SAB - Adviseren - Institut Jules Bordet
1 Jun 2024 → 31 Dec 3999
Lid SAB - Adviseren - EuroBio
1 Jun 2024 → 31 Dec 3999
Senior (gast)onderzoeker - Senior (gast)onderzoeker - Prinses Maxima Centrum
1 Jun 2024 → 31 Dec 2024
Member Board - Adviseren - Trained Immunity Discovery
1 Jan 2024 → 31 Dec 3999
Lid IDMC - Adviseren - IQVIA
1 Jan 2023 → 31 Dec 3999
Lid IDMC - Adviseren - Pfizer
1 Jan 2022 → 31 Dec 3999
Lid SAB - Adviseren - IO Biotech
1 Jan 2022 → 31 Dec 3999
CMO - CMO - SAIROPA BV
1 Jan 2022 → 31 Dec 3999
Lid IDMC - Adviseren - Boehringel Ingelheim
1 Jan 2022 → 31 Dec 3999
Lid IDMC (independent data monitoring committee) - Adviseren - BioNTech
1 Jan 2022 → 31 Dec 3999
Voorzitter Steering Committee en Voorzitter Vorstand - Besturen en adviseren - Comprehensive Cancer Center Munich
1 Jan 2022 → 31 Dec 3999
Lid SAB - Adviseren - CatalYm
1 Jan 2021 → 31 Dec 3999
Lid SAB (Scientific adboard) - Lid SAB - BIOINVENT
1 Jan 2020 → 31 Dec 3999
Adviseur Trials - Adviseur Trials - Merck & Co and MSD Europe/NL
1 Jan 2020 → 31 Dec 3999
Voorzitter - Charity bestuur voorzitten/adviseren - FOCA (FOndation CAncer)
1 Jan 2019 → 31 Dec 3999
CMO - Adviseren - Skyline DX BV
1 Jan 2019 → 31 Dec 3999
Coordinator Comprehensive Cancer Center Program - Audits - Deutsche Krebshilfe
1 Jan 2019 → 31 Dec 3999
Lid Raad van Toezicht - Adviseren - EORTC
1 Jan 2018 → 31 Dec 3999
Adviseur - Adviseren - Forbion
1 Jan 2018 → 31 Dec 2024
President 2014-2019 / Member Steering Cie 2019-2024 - Adviseren, Policy making - European Academy Cancer Sciences (EACS)
1 Jan 2014 → 31 Dec 3999
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Immunosurveillance in clinical cancer management
Kroemer, G., Chan, T. A., Eggermont, A. M. M. & Galluzzi, L., 1 Mar 2024, In: CA Cancer Journal for Clinicians. 74, 2, p. 187-202 16 p.Research output: Contribution to journal › Review article › peer-review
Open AccessFile -
Influence of microbiota-associated metabolic reprogramming on clinical outcome in patients with melanoma from the randomized adjuvant dendritic cell-based MIND-DC trial
Alves Costa Silva, C., Piccinno, G., Suissa, D., Bourgin, M., Schreibelt, G., Durand, S., Birebent, R., Fidelle, M., Sow, C., Aprahamian, F., Manghi, P., Punčochář, M., Asnicar, F., Pinto, F., Armanini, F., Terrisse, S., Routy, B., Drubay, D., Eggermont, A. M. M. & Kroemer, G. & 5 others, , 23 Feb 2024, In: Nature Communications. 15, 1, 16 p., 1633.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile -
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial
Schadendorf, D., Luke, J. J., Ascierto, P. A., Long, G. V., Rutkowski, P., Khattak, A., Del Vecchio, M., De La Cruz-Merino, L., Mackiewicz, J., Sileni, V. C., Kirkwood, J. M., Robert, C., Grob, J. J., Dummer, R., Carlino, M. S., Zhao, Y., Kalabis, M., Krepler, C., Center München, Munich, Germany, C. & Scolyer, R. A., 13 Mar 2024, In: Journal for ImmunoTherapy of Cancer. 12, 3, e007501.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile1 Downloads (Pure) -
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study
Luke, J. J., Ascierto, P. A., Khattak, M. A., De La Cruz Merino, L., Del Vecchio, M., Rutkowski, P., Spagnolo, F., Mackiewicz, J., Chiarion-Sileni, V., Kirkwood, J. M., Robert, C., Grob, J. J., De Galitiis, F., Schadendorf, D., Carlino, M. S., Wu, X. L., Fukunaga-Kalabis, M., Krepler, C., Center München, Munich, Germany, C. & Long, G. V., 10 May 2024, In: Journal of Clinical Oncology. 42, 14, p. 1619-1624 6 p.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile -
Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
Kennedy, O. J., Glassee, N., Kicinski, M., Blank, C. U., Long, G. V., Atkinson, V. G., Dalle, S., Haydon, A. M., Meshcheryakov, A., Khattak, A., Carlino, M. S., Sandhu, S., Larkin, J., Puig, S., Ascierto, P. A., Rutkowski, P., Schadendorf, D., Boers-Sonderen, M., Giacomo, A. M. D. & van den Eertwegh, A. J. M. & 12 others, , Apr 2024, In: European Journal of Cancer. 201, 113585.Research output: Contribution to journal › Article › Academic › peer-review